Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sarcoma-like appearance but pathologic Hodgkin lymphoma.
Harada S, Ando J, Ando M, Azusawa Y, Ochiai T, Hashimoto Y, Hirasawa Y, Komatsu N. Harada S, et al. Among authors: hirasawa y. Int J Hematol. 2021 Jul;114(1):1-2. doi: 10.1007/s12185-021-03169-9. Epub 2021 May 31. Int J Hematol. 2021. PMID: 34059996 No abstract available.
[A CASE COMPLAINING OF RELAPSING FEVER AND SUBCUTANEOUS NODULES].
SATO Y, WASHIO M, OMATA N, MAJIMA T, HIRASAWA Y, HAYAKAWA H, OGAWA I, ODAWA K, OGIMA I, AKAI A, ONISHI Y, KITAMURA S, OGURO C. SATO Y, et al. Among authors: hirasawa y. Newsl Int Coll Dent India Sect. 1964 Aug;78:284-92. Newsl Int Coll Dent India Sect. 1964. PMID: 14199487 Swedish. No abstract available.
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T, Matsuda T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Tsuchida S, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: hirasawa y. Target Oncol. 2024 May 28. doi: 10.1007/s11523-024-01068-7. Online ahead of print. Target Oncol. 2024. PMID: 38807017
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Murayama M, et al. Among authors: hirasawa y. Sci Rep. 2024 May 17;14(1):11325. doi: 10.1038/s41598-024-59677-1. Sci Rep. 2024. PMID: 38760458 Free PMC article.
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
Oxomollugin, an oxidized substance in mollugin, inhibited LPS-induced NF-κB activation via the suppressive effects on essential activation factors of TLR4 signaling.
Nakajima Y, Tsuboi N, Katori K, Waili M, Nugroho AE, Takahashi K, Nishino H, Hirasawa Y, Kawasaki Y, Goda Y, Kaneda T, Morita H. Nakajima Y, et al. Among authors: hirasawa y. J Nat Med. 2024 Jun;78(3):568-575. doi: 10.1007/s11418-024-01798-y. Epub 2024 Apr 2. J Nat Med. 2024. PMID: 38564154
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: hirasawa y. Target Oncol. 2024 May;19(3):401-410. doi: 10.1007/s11523-024-01047-y. Epub 2024 Mar 28. Target Oncol. 2024. PMID: 38546942
675 results